NCT01884597View on ClinicalTrials.gov

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
PCVPolypoidal Choroidal Vasculopathy
Interventions
DRUG

high-dose ranibizumab

20mg ranibizumab vials, 0.05ml injected intravitreally, monthly

DRUG

ranibizumab

3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly

Trial Locations (3)

96701

Retina Consultants of Hawaii, ‘Aiea

The Retina Center at Pali Momi, ‘Aiea

96817

Retina Consultants of Hawaii, Honolulu

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Hawaii Pacific Health

OTHER

NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) | Biotech Hunter | Biotech Hunter